Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota
Ovarian cancer has the highest mortality among all gynecological malignancies; currently, no effective therapeutics are available for its treatment. Naringenin has been shown to inhibit the progression of various cancers, but its inhibitory effect on ovarian cancer remains unknown. This study aimed...
Saved in:
| Published in | Phytomedicine (Stuttgart) Vol. 106; p. 154401 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Elsevier GmbH
01.11.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Ovarian cancer has the highest mortality among all gynecological malignancies; currently, no effective therapeutics are available for its treatment. Naringenin has been shown to inhibit the progression of various cancers, but its inhibitory effect on ovarian cancer remains unknown.
This study aimed to evaluate the inhibitory effects of naringenin on ovarian cancer and elucidate the underlying mechanisms.
Cancer cell proliferation was detected by cell counting kit-8 and crystal violet assays, and the migration capability was determined by wound healing and transwell assays. Western blotting and immunohistochemistry assays were employed to determine the expression levels of the epidermal growth factor receptor, phosphatidylinositol 3-kinase (PI3K) and cyclin D1 in vitro and in vivo, respectively. An ES-2 xenograft nude mouse model was established for the in vivo experiments, and fecal samples were collected for intestinal microbiota analysis by 16S rDNA sequencing.
Naringenin suppressed the proliferation and migration of A2780 and ES-2 cancer cell lines and downregulated PI3K in vitro. In animal experiments, naringenin treatment significantly decreased the tumor weight and volume, and oral administration exhibited greater effects than intraperitoneal injection. Additionally, naringenin treatment ameliorated the population composition of the microbiota in animals with ovarian cancer and significantly increased the abundances of Alistipes and Lactobacillus.
Naringenin suppresses epithelial ovarian cancer by inhibiting PI3K pathway expression and ameliorating the gut microbiota, and the oral route is more effective than parenteral administration. |
|---|---|
| AbstractList | BACKGROUNDOvarian cancer has the highest mortality among all gynecological malignancies; currently, no effective therapeutics are available for its treatment. Naringenin has been shown to inhibit the progression of various cancers, but its inhibitory effect on ovarian cancer remains unknown. PURPOSEThis study aimed to evaluate the inhibitory effects of naringenin on ovarian cancer and elucidate the underlying mechanisms. METHODSCancer cell proliferation was detected by cell counting kit-8 and crystal violet assays, and the migration capability was determined by wound healing and transwell assays. Western blotting and immunohistochemistry assays were employed to determine the expression levels of the epidermal growth factor receptor, phosphatidylinositol 3-kinase (PI3K) and cyclin D1 in vitro and in vivo, respectively. An ES-2 xenograft nude mouse model was established for the in vivo experiments, and fecal samples were collected for intestinal microbiota analysis by 16S rDNA sequencing. RESULTSNaringenin suppressed the proliferation and migration of A2780 and ES-2 cancer cell lines and downregulated PI3K in vitro. In animal experiments, naringenin treatment significantly decreased the tumor weight and volume, and oral administration exhibited greater effects than intraperitoneal injection. Additionally, naringenin treatment ameliorated the population composition of the microbiota in animals with ovarian cancer and significantly increased the abundances of Alistipes and Lactobacillus. CONCLUSIONNaringenin suppresses epithelial ovarian cancer by inhibiting PI3K pathway expression and ameliorating the gut microbiota, and the oral route is more effective than parenteral administration. Ovarian cancer has the highest mortality among all gynecological malignancies; currently, no effective therapeutics are available for its treatment. Naringenin has been shown to inhibit the progression of various cancers, but its inhibitory effect on ovarian cancer remains unknown. This study aimed to evaluate the inhibitory effects of naringenin on ovarian cancer and elucidate the underlying mechanisms. Cancer cell proliferation was detected by cell counting kit-8 and crystal violet assays, and the migration capability was determined by wound healing and transwell assays. Western blotting and immunohistochemistry assays were employed to determine the expression levels of the epidermal growth factor receptor, phosphatidylinositol 3-kinase (PI3K) and cyclin D1 in vitro and in vivo, respectively. An ES-2 xenograft nude mouse model was established for the in vivo experiments, and fecal samples were collected for intestinal microbiota analysis by 16S rDNA sequencing. Naringenin suppressed the proliferation and migration of A2780 and ES-2 cancer cell lines and downregulated PI3K in vitro. In animal experiments, naringenin treatment significantly decreased the tumor weight and volume, and oral administration exhibited greater effects than intraperitoneal injection. Additionally, naringenin treatment ameliorated the population composition of the microbiota in animals with ovarian cancer and significantly increased the abundances of Alistipes and Lactobacillus. Naringenin suppresses epithelial ovarian cancer by inhibiting PI3K pathway expression and ameliorating the gut microbiota, and the oral route is more effective than parenteral administration. |
| ArticleNumber | 154401 |
| Author | Lin, Huihui Lin, Yiru Gao, Zixiang Yang, Hao Zeng, Zheng Cao, Danli Wang, Wenxue Lin, Caiji Chen, Hang Zhao, Yufan Luo, Yao Liu, Huidi Yang, Jiaming Shi, Yongwei Xie, Kaihong Wang, Pengfei Luo, LingJie Liu, Shu-Lin |
| Author_xml | – sequence: 1 givenname: Caiji surname: Lin fullname: Lin, Caiji organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 2 givenname: Zheng surname: Zeng fullname: Zeng, Zheng organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 3 givenname: Yiru surname: Lin fullname: Lin, Yiru organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 4 givenname: Pengfei surname: Wang fullname: Wang, Pengfei organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 5 givenname: Danli surname: Cao fullname: Cao, Danli organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 6 givenname: Kaihong surname: Xie fullname: Xie, Kaihong organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 7 givenname: Yao surname: Luo fullname: Luo, Yao organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 8 givenname: Hao surname: Yang fullname: Yang, Hao organization: Department of Pathology, Harbin Chest Hospital, Harbin 150056, China – sequence: 9 givenname: Jiaming surname: Yang fullname: Yang, Jiaming organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 10 givenname: Wenxue surname: Wang fullname: Wang, Wenxue organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 11 givenname: LingJie surname: Luo fullname: Luo, LingJie organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 12 givenname: Huihui surname: Lin fullname: Lin, Huihui organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 13 givenname: Hang surname: Chen fullname: Chen, Hang organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 14 givenname: Yufan surname: Zhao fullname: Zhao, Yufan organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 15 givenname: Yongwei surname: Shi fullname: Shi, Yongwei organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 16 givenname: Zixiang surname: Gao fullname: Gao, Zixiang organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 17 givenname: Huidi surname: Liu fullname: Liu, Huidi email: hdliu@hrbmu.edu.cn organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China – sequence: 18 givenname: Shu-Lin surname: Liu fullname: Liu, Shu-Lin email: slliu@hrbmu.edu.cn organization: Genomics Research Center (State-Province Key Laboratory of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin 150081, China |
| BookMark | eNp9kMtq3DAUhkVJoZO0b9CFlt14oiPLF20KIeRSGNJNC90JWT7OnMGWHMkOzNtXqbvO6iz-C__5LtmFDx4Z-wpiDwLq69N-Pp4n7PdSSLmHSikBH9gOamgLoas_F2wntFJFA1B-YpcpnYQApRuxY_RkI_ln9OR5Wuc5YkqYOM60HHEkO_Lwmh3Wc2e9w8i7Myd_pI6WHONzDCMNGO1CwXPrez6Ffh3tP_F5XfhELoaOwmI_s4-DHRN--X-v2O_7u1-3j8Xh58OP25tD4cq2Wgpdga4b3etWY9-J3rpO2aoVIJWoB5CVs7ayddeUdVt2gFBnQcuhkVpK7aC8Yt-23rztZcW0mImSw3G0HsOajGxEU0OjSp2tarPmjSlFHMwcabLxbECYN7LmZDay5o2s2cjm2PcthvmNV8JokiPMdHqK6BbTB3q_4C-uU4cq |
| CitedBy_id | crossref_primary_10_1016_j_jep_2024_118438 crossref_primary_10_1016_j_phrs_2024_107148 crossref_primary_10_3390_app13063663 crossref_primary_10_3390_nu15020319 crossref_primary_10_1111_bph_16397 crossref_primary_10_1007_s12668_023_01288_7 crossref_primary_10_1007_s12291_024_01222_y crossref_primary_10_1615_CritRevImmunol_2023051509 crossref_primary_10_2147_IJWH_S462883 crossref_primary_10_1002_aac2_12071 crossref_primary_10_1080_19490976_2023_2236749 crossref_primary_10_1134_S0965545X23700785 crossref_primary_10_2174_0115680096267430231023091521 crossref_primary_10_1016_j_jnutbio_2023_109448 crossref_primary_10_1021_acs_jnatprod_3c00782 crossref_primary_10_1039_D3FO00123G |
| Cites_doi | 10.1080/01635581.2019.1656756 10.1007/s00404-014-3377-3 10.3322/caac.21456 10.1093/chrsci/49.4.316 10.1002/mnfr.201500379 10.3322/caac.21559 10.1016/j.semcancer.2019.05.012 10.1016/j.phrs.2020.105264 10.1038/s41591-019-0509-0 10.1016/j.ygyno.2019.09.002 10.1016/j.toxlet.2015.06.012 10.1007/s13238-011-1056-8 10.1021/acsinfecdis.0c00839 10.1016/j.ejca.2021.03.009 10.1016/j.jep.2021.113835 10.1186/s13058-016-0698-0 10.1155/2021/4304507 10.1038/nrclinonc.2013.5 10.1007/s11010-010-0708-y 10.1016/j.bpobgyn.2016.08.006 10.1002/tox.22677 10.3390/nu11071464 10.1002/mnfr.201300045 10.1016/S1470-2045(15)00366-6 10.3322/caac.21660 10.1016/j.phymed.2017.08.026 10.1007/s00281-012-0352-6 10.1007/s00394-016-1312-z 10.1016/j.micpath.2017.12.043 10.1038/bjc.2011.62 |
| ContentType | Journal Article |
| Copyright | 2022 |
| Copyright_xml | – notice: 2022 |
| DBID | 6I. AAFTH AAYXX CITATION 7X8 |
| DOI | 10.1016/j.phymed.2022.154401 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1618-095X |
| EndPage | 154401 |
| ExternalDocumentID | 10_1016_j_phymed_2022_154401 S0944711322004901 |
| GroupedDBID | --- --K --M .~1 0R~ 123 1B1 1~. 1~5 29O 3V. 4.4 457 4G. 53G 5VS 6I. 7-5 71M 7RV 7X2 7X7 88E 88I 8AF 8FE 8FH 8FI 8FJ 8P~ 8R4 8R5 9JM AABNK AACTN AAEDT AAEDW AAFTH AAIAV AAIKJ AAKOC AAKPP AALRI AAOAW AAQFI AAQXK AATCM AAWTL AAXUO AAYOK ABBQC ABFNM ABFRF ABGSF ABJNI ABLVK ABMAC ABMZM ABUDA ABUWG ABXDB ABYKQ ABZDS ACDAQ ACGFO ACGFS ACGOD ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKRA AFKWA AFRAH AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AHHHB AHMBA AIEXJ AIKHN AITUG AIXEN AJBFU AJOXV AJRQY ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG ATCPS AVWKF AXJTR AZFZN AZQEC BENPR BES BHPHI BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CAG CCPQU COF CS3 DOVZS DU5 DWQXO EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ HCIFZ HMCUK HVGLF HX~ HZ~ IAG IAO IEA IHA IHE IHR INH INR IOF ISR J1W KOM LCYCR M0K M1P M2P M2Q M41 MO0 N9A NAPCQ O-L O9- OAUVE OGGZJ OZT P-8 P-9 P2P PC. PCD PQQKQ PROAC PSQYO PV9 Q2X Q38 R2- RIG ROL RPZ RWL RXW RZL S0X SCC SDF SDG SEL SES SEW SPCBC SSH SSP SSU SSZ T5I T5K TAE UKHRP UNMZH WOW ~G- ~KM AAHBH AAXKI AAYXX AFJKZ AKRWK ALIPV CITATION ITC 7X8 |
| ID | FETCH-LOGICAL-c385t-9519679d989edb0dacb4a58012406f125caa5a6b73683b1e1624092f729229c13 |
| IEDL.DBID | .~1 |
| ISSN | 0944-7113 |
| IngestDate | Fri Aug 16 05:15:17 EDT 2024 Thu Sep 26 15:51:26 EDT 2024 Fri Feb 23 02:40:41 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Gut microbiota PCoA Naringenin IHC p.o., per os i.p NMDS PFA EGFR Ovarian cancer PCA MMP PI3K CCND1 CMC-Na EOC HE HPLC |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c385t-9519679d989edb0dacb4a58012406f125caa5a6b73683b1e1624092f729229c13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0944711322004901 |
| PQID | 2707617439 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | proquest_miscellaneous_2707617439 crossref_primary_10_1016_j_phymed_2022_154401 elsevier_sciencedirect_doi_10_1016_j_phymed_2022_154401 |
| PublicationCentury | 2000 |
| PublicationDate | November 2022 2022-11-00 20221101 |
| PublicationDateYYYYMMDD | 2022-11-01 |
| PublicationDate_xml | – month: 11 year: 2022 text: November 2022 |
| PublicationDecade | 2020 |
| PublicationTitle | Phytomedicine (Stuttgart) |
| PublicationYear | 2022 |
| Publisher | Elsevier GmbH |
| Publisher_xml | – name: Elsevier GmbH |
| References | Sheng, Liu (bib0022) 2011; 104 Ediriweera, Tennekoon, Samarakoon (bib0006) 2019 Li, Zhang, Yang, Wang, Wang, Huang, Zhang (bib0015) 2021; 2021 Park, Lim, Bazer, Song (bib0018) 2018; 50 Haque, Brazeau, Amin (bib0008) 2021; 149 Memariani, Abbas, ul Hassan, Ahmadi, Chabra (bib0016) 2021; 171 Kumar, Bhan Tiku (bib0012) 2020; 72 Grivennikov (bib0007) 2013; 35 Wan, Sun, Wang, Li, Yu, Guo (bib0028) 2011; 49 Qi, Yun, Sun, Xia, Wu, Wang, Wang, Zhang, Liang, Wang, Gonzalez, Patterson, Liu, Mu, Zhou, Zhao, Li, Liu, Zhong, Pang, Jiang, Qiao (bib0020) 2019; 25 Borella, Carosso, Cosma, Preti, Collemi, Cassoni, Bertero, Benedetto (bib0001) 2021; 7 Yang, Trevethan, Wang, Zhao (bib0032) 2022; 108967 Ke, Cole, Hamad, Hsiao, Cotten, Powell, Belury (bib0011) 2016; 60 Chen, Chang, Wang, Chen, Hseu, Chen, Yeh, Chen, Hsu (bib0003) 2019; 34 Coleman, Monk, Sood, Herzog (bib0004) 2013; 10 Sung, Ferlay, Siegel, Laversanne, Soerjomataram, Jemal, Bray (bib0026) 2021; 71 Sousa, Duarte, Silva-Lima, Videira (bib0024) 2021; 0 Chen, Du, Huang, Jia, Tie, Fan, Zhou, Chen, Bo (bib0002) 2021; 270 Sims, Colbert, Zheng, Delgado Medrano, Hoffman, Ramondetta, Jazaeri, Jhingran, Schmeler, Daniel, Klopp (bib0023) 2019; 155 Webb, Jordan (bib0030) 2017; 41 Pereira-Caro, Fernández-Quirós, Ludwig, Pradas, Crozier, Moreno-Rojas (bib0019) 2018; 57 Zhang, Dong, Zeng, Zhang, Zhang, Qiu, Wang, Yin, Zhang, Liang (bib0033) 2016; 18 Jiang, Wang, Hou, Liu, Zhang, Jiang (bib0009) 2018; 115 Lheureux, Braunstein, Oza (bib0013) 2019; 69 Li, Zeng, Shen (bib0014) 2014; 290 Qin, Jin, Lu, Lu, Zhang, Zhang, Liang (bib0021) 2011; 2 Stevens, Rymenant, Grootaert, Camp, Possemiers, Masclee, Jonkers (bib0025) 2019; 11 du Bois, Kristensen, Ray-Coquard, Reuss, Pignata, Colombo, Denison, Vergote, Del Campo, Ottevanger, Heubner, Minarik, Sevin, de Gregorio, Bidziński, Pfisterer, Malander, Hilpert, Mirza, Scambia, Meier, Nicoletto, Bjørge, Lortholary, Sailer, Merger, Harter (bib0005) 2016; 17 Karasawa, Steyger (bib0010) 2015; 237 Wang, Xie, Dong, Mei, Zhao, Leng, Hu, Li, Gu, Zhao (bib0029) 2020; 16 Yang, Li, Zhou, Kolosov, Perelman (bib0031) 2011; 351 Noda, Tanabe, Suzuki (bib0017) 2013; 57 Torre, Trabert, DeSantis, Miller, Samimi, Runowicz, Gaudet, Jemal, Siegel (bib0027) 2018; 68 Jiang (10.1016/j.phymed.2022.154401_bib0009) 2018; 115 Lheureux (10.1016/j.phymed.2022.154401_bib0013) 2019; 69 Sims (10.1016/j.phymed.2022.154401_bib0023) 2019; 155 Yang (10.1016/j.phymed.2022.154401_bib0031) 2011; 351 Kumar (10.1016/j.phymed.2022.154401_bib0012) 2020; 72 du Bois (10.1016/j.phymed.2022.154401_bib0005) 2016; 17 Wan (10.1016/j.phymed.2022.154401_bib0028) 2011; 49 Coleman (10.1016/j.phymed.2022.154401_bib0004) 2013; 10 Torre (10.1016/j.phymed.2022.154401_bib0027) 2018; 68 Chen (10.1016/j.phymed.2022.154401_bib0003) 2019; 34 Zhang (10.1016/j.phymed.2022.154401_bib0033) 2016; 18 Chen (10.1016/j.phymed.2022.154401_bib0002) 2021; 270 Li (10.1016/j.phymed.2022.154401_bib0015) 2021; 2021 Memariani (10.1016/j.phymed.2022.154401_bib0016) 2021; 171 Noda (10.1016/j.phymed.2022.154401_bib0017) 2013; 57 Qi (10.1016/j.phymed.2022.154401_bib0020) 2019; 25 Ke (10.1016/j.phymed.2022.154401_bib0011) 2016; 60 Qin (10.1016/j.phymed.2022.154401_bib0021) 2011; 2 Haque (10.1016/j.phymed.2022.154401_bib0008) 2021; 149 Li (10.1016/j.phymed.2022.154401_bib0014) 2014; 290 Park (10.1016/j.phymed.2022.154401_bib0018) 2018; 50 Sung (10.1016/j.phymed.2022.154401_bib0026) 2021; 71 Yang (10.1016/j.phymed.2022.154401_bib0032) 2022; 108967 Karasawa (10.1016/j.phymed.2022.154401_bib0010) 2015; 237 Sheng (10.1016/j.phymed.2022.154401_bib0022) 2011; 104 Borella (10.1016/j.phymed.2022.154401_bib0001) 2021; 7 Sousa (10.1016/j.phymed.2022.154401_bib0024) 2021; 0 Ediriweera (10.1016/j.phymed.2022.154401_bib0006) 2019 Grivennikov (10.1016/j.phymed.2022.154401_bib0007) 2013; 35 Pereira-Caro (10.1016/j.phymed.2022.154401_bib0019) 2018; 57 Wang (10.1016/j.phymed.2022.154401_bib0029) 2020; 16 Webb (10.1016/j.phymed.2022.154401_bib0030) 2017; 41 Stevens (10.1016/j.phymed.2022.154401_bib0025) 2019; 11 |
| References_xml | – volume: 34 start-page: 233 year: 2019 end-page: 239 ident: bib0003 article-title: Naringenin inhibited migration and invasion of glioblastoma cells through multiple mechanisms publication-title: Environ. Toxicol. contributor: fullname: Hsu – volume: 351 start-page: 29 year: 2011 end-page: 40 ident: bib0031 article-title: Naringenin attenuates mucous hypersecretion by modulating reactive oxygen species production and inhibiting NF-κB activity via EGFR-PI3K-Akt/ERK MAPKinase signaling in human airway epithelial cells publication-title: Mol. Cell. Biochem. contributor: fullname: Perelman – year: 2019 ident: bib0006 article-title: Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance publication-title: Semin. Cancer Biol. contributor: fullname: Samarakoon – volume: 104 start-page: 1241 year: 2011 end-page: 1245 ident: bib0022 article-title: The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer publication-title: Br. J. Cancer contributor: fullname: Liu – volume: 35 start-page: 229 year: 2013 end-page: 244 ident: bib0007 article-title: Inflammation and colorectal cancer: colitis-associated neoplasia publication-title: Semin. Immunopathol. contributor: fullname: Grivennikov – volume: 290 start-page: 1067 year: 2014 end-page: 1078 ident: bib0014 article-title: PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer publication-title: Arch. Gynecol. Obstet. contributor: fullname: Shen – volume: 57 start-page: 231 year: 2018 end-page: 242 ident: bib0019 article-title: Catabolism of citrus flavanones by the probiotics Bifidobacterium longum and Lactobacillus rhamnosus publication-title: Eur. J. Nutr. contributor: fullname: Moreno-Rojas – volume: 16 year: 2020 ident: bib0029 article-title: Clinically approved carbon nanoparticles with oral administration for intestinal radioprotection via protecting the small intestinal crypt stem cells and maintaining the balance of intestinal flora publication-title: Small contributor: fullname: Zhao – volume: 10 start-page: 211 year: 2013 end-page: 224 ident: bib0004 article-title: Latest research and treatment of advanced-stage epithelial ovarian cancer publication-title: Nat. Rev. Clin. Oncol. contributor: fullname: Herzog – volume: 25 start-page: 1225 year: 2019 end-page: 1233 ident: bib0020 article-title: Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome publication-title: Nat. Med. contributor: fullname: Qiao – volume: 237 start-page: 219 year: 2015 end-page: 227 ident: bib0010 article-title: An integrated view of cisplatin-induced nephrotoxicity and ototoxicity publication-title: Toxicol. Lett. contributor: fullname: Steyger – volume: 108967 year: 2022 ident: bib0032 article-title: Beneficial effects of citrus flavanones naringin and naringenin and their food sources on lipid metabolism: an update on bioavailability, pharmacokinetics, and mechanisms publication-title: J. Nutr. Biochem. contributor: fullname: Zhao – volume: 17 start-page: 78 year: 2016 end-page: 89 ident: bib0005 article-title: Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial publication-title: Lancet. Oncol. contributor: fullname: Harter – volume: 0 start-page: 1 year: 2021 end-page: 15 ident: bib0024 article-title: Repurposing natural dietary flavonoids in the modulation of cancer tumorigenesis: decrypting the molecular targets of Naringenin, Hesperetin and myricetin publication-title: Nutr. Cancer contributor: fullname: Videira – volume: 7 start-page: 987 year: 2021 end-page: 1009 ident: bib0001 article-title: Gut microbiota and gynecological cancers: a summary of pathogenetic mechanisms and future directions publication-title: ACS Infect. Dis. contributor: fullname: Benedetto – volume: 50 start-page: 238 year: 2018 end-page: 246 ident: bib0018 article-title: Naringenin suppresses growth of human placental choriocarcinoma via reactive oxygen species-mediated P38 and JNK MAPK pathways publication-title: Phytomedicine contributor: fullname: Song – volume: 68 year: 2018 ident: bib0027 article-title: Ovarian cancer statistics, 2018 publication-title: CA. Cancer J. Clin. contributor: fullname: Siegel – volume: 149 start-page: 165 year: 2021 end-page: 183 ident: bib0008 article-title: Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds publication-title: Eur. J. Cancer contributor: fullname: Amin – volume: 60 start-page: 313 year: 2016 end-page: 324 ident: bib0011 article-title: Citrus flavonoid, naringenin, increases locomotor activity and reduces diacylglycerol accumulation in skeletal muscle of obese ovariectomized mice publication-title: Mol. Nutr. Food Res. contributor: fullname: Belury – volume: 2 start-page: 507 year: 2011 end-page: 516 ident: bib0021 article-title: Naringenin reduces lung metastasis in a breast cancer resection model publication-title: Protein Cell contributor: fullname: Liang – volume: 11 year: 2019 ident: bib0025 article-title: The intestinal fate of citrus flavanones and their effects on gastrointestinal health publication-title: Nutrients contributor: fullname: Jonkers – volume: 41 start-page: 3 year: 2017 end-page: 14 ident: bib0030 article-title: Epidemiology of epithelial ovarian cancer publication-title: Best Pract. Res. Clin. Obstet. Gynaecol. contributor: fullname: Jordan – volume: 171 year: 2021 ident: bib0016 article-title: Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: efficacy and molecular mechanisms of action, a comprehensive narrative review publication-title: Pharmacol. Res. contributor: fullname: Chabra – volume: 49 start-page: 316 year: 2011 end-page: 320 ident: bib0028 article-title: A stereospecific HPLC method and its application in determination of pharmacokinetics profile of two enantiomers of naringenin in rats publication-title: J. Chromatogr. Sci. contributor: fullname: Guo – volume: 155 start-page: 237 year: 2019 end-page: 244 ident: bib0023 article-title: Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls publication-title: Gynecol. Oncol. contributor: fullname: Klopp – volume: 71 start-page: 209 year: 2021 end-page: 249 ident: bib0026 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries publication-title: CA. Cancer J. Clin. contributor: fullname: Bray – volume: 2021 year: 2021 ident: bib0015 article-title: The Mechanism of Xiaoyao San in the Treatment of Ovarian Cancer by Network Pharmacology and the Effect of Stigmasterol on the PI3K/Akt Pathway publication-title: Dis. Markers contributor: fullname: Zhang – volume: 57 start-page: 2019 year: 2013 end-page: 2028 ident: bib0017 article-title: Naringenin enhances intestinal barrier function through the expression and cytoskeletal association of tight junction proteins in Caco-2 cells publication-title: Mol. Nutr. Food Res. contributor: fullname: Suzuki – volume: 115 start-page: 179 year: 2018 end-page: 182 ident: bib0009 article-title: Hydromethanolic extract of Rehum emodi exhibits significant antimicrobial activity against acute gastroenteriti bacterial strains publication-title: Microb. Pathog. contributor: fullname: Jiang – volume: 270 year: 2021 ident: bib0002 article-title: Gut microbiota affects the efficacy of Danggui Buxue Tang by affecting plasma concentration of active ingredients publication-title: J. Ethnopharmacol. contributor: fullname: Bo – volume: 72 start-page: 976 year: 2020 end-page: 983 ident: bib0012 article-title: Naringenin Suppresses Chemically Induced Skin Cancer in Two-Stage Skin Carcinogenesis Mouse Model publication-title: Nutr. Cancer contributor: fullname: Bhan Tiku – volume: 69 start-page: 280 year: 2019 end-page: 304 ident: bib0013 article-title: Epithelial ovarian cancer: evolution of management in the era of precision medicine publication-title: CA Cancer J. Clin. contributor: fullname: Oza – volume: 18 start-page: 1 year: 2016 end-page: 16 ident: bib0033 article-title: Naringenin prevents TGF-β1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation publication-title: Breast Cancer Res contributor: fullname: Liang – volume: 72 start-page: 976 year: 2020 ident: 10.1016/j.phymed.2022.154401_bib0012 article-title: Naringenin Suppresses Chemically Induced Skin Cancer in Two-Stage Skin Carcinogenesis Mouse Model publication-title: Nutr. Cancer doi: 10.1080/01635581.2019.1656756 contributor: fullname: Kumar – volume: 290 start-page: 1067 year: 2014 ident: 10.1016/j.phymed.2022.154401_bib0014 article-title: PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer publication-title: Arch. Gynecol. Obstet. doi: 10.1007/s00404-014-3377-3 contributor: fullname: Li – volume: 68 year: 2018 ident: 10.1016/j.phymed.2022.154401_bib0027 article-title: Ovarian cancer statistics, 2018 publication-title: CA. Cancer J. Clin. doi: 10.3322/caac.21456 contributor: fullname: Torre – volume: 49 start-page: 316 year: 2011 ident: 10.1016/j.phymed.2022.154401_bib0028 article-title: A stereospecific HPLC method and its application in determination of pharmacokinetics profile of two enantiomers of naringenin in rats publication-title: J. Chromatogr. Sci. doi: 10.1093/chrsci/49.4.316 contributor: fullname: Wan – volume: 60 start-page: 313 year: 2016 ident: 10.1016/j.phymed.2022.154401_bib0011 article-title: Citrus flavonoid, naringenin, increases locomotor activity and reduces diacylglycerol accumulation in skeletal muscle of obese ovariectomized mice publication-title: Mol. Nutr. Food Res. doi: 10.1002/mnfr.201500379 contributor: fullname: Ke – volume: 69 start-page: 280 year: 2019 ident: 10.1016/j.phymed.2022.154401_bib0013 article-title: Epithelial ovarian cancer: evolution of management in the era of precision medicine publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21559 contributor: fullname: Lheureux – year: 2019 ident: 10.1016/j.phymed.2022.154401_bib0006 article-title: Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2019.05.012 contributor: fullname: Ediriweera – volume: 171 year: 2021 ident: 10.1016/j.phymed.2022.154401_bib0016 article-title: Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: efficacy and molecular mechanisms of action, a comprehensive narrative review publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2020.105264 contributor: fullname: Memariani – volume: 25 start-page: 1225 year: 2019 ident: 10.1016/j.phymed.2022.154401_bib0020 article-title: Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome publication-title: Nat. Med. doi: 10.1038/s41591-019-0509-0 contributor: fullname: Qi – volume: 155 start-page: 237 year: 2019 ident: 10.1016/j.phymed.2022.154401_bib0023 article-title: Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2019.09.002 contributor: fullname: Sims – volume: 237 start-page: 219 year: 2015 ident: 10.1016/j.phymed.2022.154401_bib0010 article-title: An integrated view of cisplatin-induced nephrotoxicity and ototoxicity publication-title: Toxicol. Lett. doi: 10.1016/j.toxlet.2015.06.012 contributor: fullname: Karasawa – volume: 2 start-page: 507 year: 2011 ident: 10.1016/j.phymed.2022.154401_bib0021 article-title: Naringenin reduces lung metastasis in a breast cancer resection model publication-title: Protein Cell doi: 10.1007/s13238-011-1056-8 contributor: fullname: Qin – volume: 7 start-page: 987 year: 2021 ident: 10.1016/j.phymed.2022.154401_bib0001 article-title: Gut microbiota and gynecological cancers: a summary of pathogenetic mechanisms and future directions publication-title: ACS Infect. Dis. doi: 10.1021/acsinfecdis.0c00839 contributor: fullname: Borella – volume: 149 start-page: 165 year: 2021 ident: 10.1016/j.phymed.2022.154401_bib0008 article-title: Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2021.03.009 contributor: fullname: Haque – volume: 0 start-page: 1 year: 2021 ident: 10.1016/j.phymed.2022.154401_bib0024 article-title: Repurposing natural dietary flavonoids in the modulation of cancer tumorigenesis: decrypting the molecular targets of Naringenin, Hesperetin and myricetin publication-title: Nutr. Cancer contributor: fullname: Sousa – volume: 270 year: 2021 ident: 10.1016/j.phymed.2022.154401_bib0002 article-title: Gut microbiota affects the efficacy of Danggui Buxue Tang by affecting plasma concentration of active ingredients publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2021.113835 contributor: fullname: Chen – volume: 18 start-page: 1 year: 2016 ident: 10.1016/j.phymed.2022.154401_bib0033 article-title: Naringenin prevents TGF-β1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation publication-title: Breast Cancer Res doi: 10.1186/s13058-016-0698-0 contributor: fullname: Zhang – volume: 2021 year: 2021 ident: 10.1016/j.phymed.2022.154401_bib0015 article-title: The Mechanism of Xiaoyao San in the Treatment of Ovarian Cancer by Network Pharmacology and the Effect of Stigmasterol on the PI3K/Akt Pathway publication-title: Dis. Markers doi: 10.1155/2021/4304507 contributor: fullname: Li – volume: 10 start-page: 211 year: 2013 ident: 10.1016/j.phymed.2022.154401_bib0004 article-title: Latest research and treatment of advanced-stage epithelial ovarian cancer publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2013.5 contributor: fullname: Coleman – volume: 351 start-page: 29 year: 2011 ident: 10.1016/j.phymed.2022.154401_bib0031 article-title: Naringenin attenuates mucous hypersecretion by modulating reactive oxygen species production and inhibiting NF-κB activity via EGFR-PI3K-Akt/ERK MAPKinase signaling in human airway epithelial cells publication-title: Mol. Cell. Biochem. doi: 10.1007/s11010-010-0708-y contributor: fullname: Yang – volume: 41 start-page: 3 year: 2017 ident: 10.1016/j.phymed.2022.154401_bib0030 article-title: Epidemiology of epithelial ovarian cancer publication-title: Best Pract. Res. Clin. Obstet. Gynaecol. doi: 10.1016/j.bpobgyn.2016.08.006 contributor: fullname: Webb – volume: 34 start-page: 233 year: 2019 ident: 10.1016/j.phymed.2022.154401_bib0003 article-title: Naringenin inhibited migration and invasion of glioblastoma cells through multiple mechanisms publication-title: Environ. Toxicol. doi: 10.1002/tox.22677 contributor: fullname: Chen – volume: 11 year: 2019 ident: 10.1016/j.phymed.2022.154401_bib0025 article-title: The intestinal fate of citrus flavanones and their effects on gastrointestinal health publication-title: Nutrients doi: 10.3390/nu11071464 contributor: fullname: Stevens – volume: 57 start-page: 2019 year: 2013 ident: 10.1016/j.phymed.2022.154401_bib0017 article-title: Naringenin enhances intestinal barrier function through the expression and cytoskeletal association of tight junction proteins in Caco-2 cells publication-title: Mol. Nutr. Food Res. doi: 10.1002/mnfr.201300045 contributor: fullname: Noda – volume: 16 year: 2020 ident: 10.1016/j.phymed.2022.154401_bib0029 article-title: Clinically approved carbon nanoparticles with oral administration for intestinal radioprotection via protecting the small intestinal crypt stem cells and maintaining the balance of intestinal flora publication-title: Small contributor: fullname: Wang – volume: 17 start-page: 78 year: 2016 ident: 10.1016/j.phymed.2022.154401_bib0005 article-title: Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial publication-title: Lancet. Oncol. doi: 10.1016/S1470-2045(15)00366-6 contributor: fullname: du Bois – volume: 71 start-page: 209 year: 2021 ident: 10.1016/j.phymed.2022.154401_bib0026 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries publication-title: CA. Cancer J. Clin. doi: 10.3322/caac.21660 contributor: fullname: Sung – volume: 50 start-page: 238 year: 2018 ident: 10.1016/j.phymed.2022.154401_bib0018 article-title: Naringenin suppresses growth of human placental choriocarcinoma via reactive oxygen species-mediated P38 and JNK MAPK pathways publication-title: Phytomedicine doi: 10.1016/j.phymed.2017.08.026 contributor: fullname: Park – volume: 108967 year: 2022 ident: 10.1016/j.phymed.2022.154401_bib0032 article-title: Beneficial effects of citrus flavanones naringin and naringenin and their food sources on lipid metabolism: an update on bioavailability, pharmacokinetics, and mechanisms publication-title: J. Nutr. Biochem. contributor: fullname: Yang – volume: 35 start-page: 229 year: 2013 ident: 10.1016/j.phymed.2022.154401_bib0007 article-title: Inflammation and colorectal cancer: colitis-associated neoplasia publication-title: Semin. Immunopathol. doi: 10.1007/s00281-012-0352-6 contributor: fullname: Grivennikov – volume: 57 start-page: 231 year: 2018 ident: 10.1016/j.phymed.2022.154401_bib0019 article-title: Catabolism of citrus flavanones by the probiotics Bifidobacterium longum and Lactobacillus rhamnosus publication-title: Eur. J. Nutr. doi: 10.1007/s00394-016-1312-z contributor: fullname: Pereira-Caro – volume: 115 start-page: 179 year: 2018 ident: 10.1016/j.phymed.2022.154401_bib0009 article-title: Hydromethanolic extract of Rehum emodi exhibits significant antimicrobial activity against acute gastroenteriti bacterial strains publication-title: Microb. Pathog. doi: 10.1016/j.micpath.2017.12.043 contributor: fullname: Jiang – volume: 104 start-page: 1241 year: 2011 ident: 10.1016/j.phymed.2022.154401_bib0022 article-title: The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer publication-title: Br. J. Cancer doi: 10.1038/bjc.2011.62 contributor: fullname: Sheng |
| SSID | ssj0014970 |
| Score | 2.4900107 |
| Snippet | Ovarian cancer has the highest mortality among all gynecological malignancies; currently, no effective therapeutics are available for its treatment. Naringenin... BACKGROUNDOvarian cancer has the highest mortality among all gynecological malignancies; currently, no effective therapeutics are available for its treatment.... |
| SourceID | proquest crossref elsevier |
| SourceType | Aggregation Database Publisher |
| StartPage | 154401 |
| SubjectTerms | Gut microbiota Naringenin Ovarian cancer PI3K |
| Title | Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota |
| URI | https://dx.doi.org/10.1016/j.phymed.2022.154401 https://search.proquest.com/docview/2707617439 |
| Volume | 106 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS8MwEA9DQXwRnYrfRBCfjFs_0jaPIsp0OIYf6FtI2lQrmhXXCXvxb_eStA5FEHwqbdLS5q73u8t9IXSQhDnNqaQk91hMQuVLItOQkW4uAFBA4WDSRvkOot5dePlAH1rotMmFMWGVtex3Mt1K6_pKp17NTlkUnRswTECyGmvKuq9sBjuAEfD08cdXmAcYALZhnJlMzOwmfc7GeMGXAOaAlej7ZoslrFvD_AJPPwS1RZ_zZbRUq434xL3ZCmop3UYLV7VjvI0Oh64E9fQI384yqsZH-BAPZ8Wpp6uoGAi7k6cLjceT0obBqjFWpcnNeAFmxKN3mCE0Tg0_vGE5xYV-KmRh4qNxaZr85MqxDRY6w6-jzHYAg8HHSYVfC1fZqRJr6O787Pa0R-p2CyQNEloR0LVYFLOMJUxlspuJVIaCGgQD0M9BEUqFoCKScRAlgfSUF8EA83NQz32fpV6wjub0SKsNhANPeJ7IGc0E0EiJJKKgJ9Iw60oaKz_YRKRZZV66qhq8CTd75o4q3FCFO6psorghBf_GHRwE_x937jeU4_DjGG-I0Go0GXM_Nls4xh7b-vfTt9GiOXO5iTtornqbqF1QUiq5Z7lwD82fXPR7A3PsX9_3PwHweuld |
| link.rule.ids | 315,786,790,4521,24144,27957,27958,45620,45714 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS-QwEB9khbt7EfVOzs_LweGTYbdt0jaPIsp66iK4gm8haVPtcWaL2xX2v3eStCfKwcG9NklpM5OZ32S-AH7krOIV15xWkcgoM7GmumCCjiqFCgUBh9A-yneSjm_Zzzt-twInfS6MC6vsZH-Q6V5ad0-G3W4Om7oe3qBhgpLVWVPefYUm0CrjWcQGsHp8fjGe_HEmMOF7xrn51C3oM-h8mBf-DKodNBTj2N2ysK47zF801DtZ7RXQ2TqsdciRHIeP24AVYzfhw1XnG9-Ew-tQhXp5RKavSVXzI3JIrl_rUy8_Qz1R_jLP1pbMF42PhDVzYhqXnvEb-ZHMnnGGsqRwLPFE9JLU9qHWtQuRJo3r81OZwDlE2ZI8zkrfBAwH7xcteaxDcadWfYHbs9PpyZh2HRdokeS8pQi3RJqJUuTClHpUqkIzxZ0SQ71fIRYqlOIq1VmS5omOTJTigIgrROhxLIoo2YKBnVnzFUgSqShSleClQjIZlaccoSJn5UjzzMTJNtB-l2UTCmvIPuLslwxUkY4qMlBlG7KeFPINg0iU_f9Y-b2nnMSz4xwiyprZYi7jzN3iOJNs57_f_g0-jqdXl_LyfHKxC5_cSEhV3INB-7Qw-4hZWn3Q8eQLrbPqcA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Naringenin+suppresses+epithelial+ovarian+cancer+by+inhibiting+proliferation+and+modulating+gut+microbiota&rft.jtitle=Phytomedicine+%28Stuttgart%29&rft.au=Lin%2C+Caiji&rft.au=Zeng%2C+Zheng&rft.au=Lin%2C+Yiru&rft.au=Wang%2C+Pengfei&rft.date=2022-11-01&rft.eissn=1618-095X&rft.volume=106&rft.spage=154401&rft.epage=154401&rft_id=info:doi/10.1016%2Fj.phymed.2022.154401&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0944-7113&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0944-7113&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0944-7113&client=summon |